PMC7719304_01
18F-FDG PET/CT tumor imaging before treatment. (A) CT; (B) PET; (C) PET-CT fusion 1 hour after injection; (D) PET-CT fusion 2 hours after injection; (E) full-body projection shows a fused soft-tissue mass about 2.8 cm in diameter in the hilar area (left front of the inferior vena cava), with punctate high-density shadows, unclear boundaries with surrounding tissue, and abnormal concentration of imaging agent in the mass. SUVmax was 9.4, and delayed display showed SUVmax of 12.0.
IJGM-13-1335-g0001.jpg
PMC7719304_01_IJGM-13-1335-g0001.jpg
f0001
As shown on 18F-FDG PET-CT (Figure 1), a soft-tissue mass about 2.8 cm in diameter was present in the hilar area, with punctate high-density shadows, unclear borders, and abnormal concentration of imaging agent.
Enhanced CT before treatment revealed no vascular envelopment in the mass, but the mass pressing on blood vessels. (A) arterial phase cross section; (B) venous phase cross section; (C) delayed-phase cross section; (D) venous phase coronal section.
IJGM-13-1335-g0002.jpg
PMC7719304_01_IJGM-13-1335-g0002.jpg
f0002
Enhanced CT (Figure 2) revealed no vascular envelopment in the mass.
Reexamination using CT and 18F-FDG PET-CT tumor imaging 5 months after antituberculosis treatment. (A) CT; (B) PET-CT fusion 1 hour after injection. The fused soft-tissue mass in the hilar area (left front of the inferior vena cava) became smaller, with a diameter of about 1.5 cm, and the inner dots were high in density. The shadow had increased, and the boundary with surrounding tissue was still unclear. The concentration of imaging agent in the mass was lower, and SUVmax was 8.1.
IJGM-13-1335-g0003.jpg
PMC7719304_01_IJGM-13-1335-g0003.jpg
f0003
Follow-up checking using 18F-FDG PET-CT imaging (Figure 3) showed that the mass had become smaller with a diameter of about 1.5 cm, along with increased internal punctate high-density shadow and SUVmax reduced to 8.1.